$KPRX

$1.76 -$0.60 (25.42%) Close

$KPRX Overview Financial Statements SEC Filings Executives News Red Flags Capital Raising Ownership Insider Transactions Congressional Trades

Ownership

13F as of Q2 2026 · 4.4M shares outstanding

Who owns KPRX?

By type of holder

Institutions 25.0% Insiders 2.6% Everyone else 72.4%

Concentration Top 10 holders own 24.7%

Perceptive Advisors LLC 9.9% · ADAR1 Capital Management, LLC 3.8%

Institutional ownership

25.0%

+17.3 pts vs last qtr

Institutional holders

+4 vs last qtr

Net shares bought

+766.4K

by institutions in Q2 2026

New / sold out

10 / 6

positions opened vs closed

How is ownership changing?

Institutions, last 8 quarters

Biggest buyers in Q2 2026

Perceptive Advisors LLC NEW +438.5K
Two Sigma Investments, LP NEW +88.8K

Biggest sellers in Q2 2026

Geode Capital Management, LLC −21.1K
XTX Topco Ltd SOLD OUT −14.7K

Who is planning to sell?

No insider has filed a notice of proposed sale (Form 144) for Kiora Pharmaceuticals, Inc. in the last 12 months.

Is your stake being diluted?

Diluted share count, FY2024–FY2025

−0.5%

−0.51% a year

Each share's claim on the business

+0.5%

grew without buying or selling a share

Spent on buybacks vs paid in stock

— vs $1.56M

over 2 fiscal years

Diluted shares, split-adjusted

Buybacks Stock-based comp

How patient are the owners?

Institutional shares by how long they've been held

5+ years0% 3–5 years0% 1–3 years18% Under 1 year82%

Quarterly turnover

130.1%

of institutional shares changed hands

Top 10 managers, median time held

0 quarters

Super Investors

Investment managers reporting KPRX on Form 13F

Holder	Shares	% of company	Change vs last qtr	Held since	% of their book
PA Perceptive Advisors LLC	438.5K	9.91%	NEW	Q2 '26	0.0%
Shares held by quarter Peak holding438.5K (Q2'26) Change over 8 quarters+438.5K Share of the company9.910% Perceptive Advisors LLC's full portfolio →
AC ADAR1 Capital Management, LLC	167.9K	3.80%	Unchanged	2024	0.0%
Shares held by quarter Peak holding200.2K (Q4'24) Change over 8 quarters−28.6K Share of the company3.800% ADAR1 Capital Management, LLC's full portfolio →

Perceptive Advisors LLC

438.5K

% of company

9.91%

Change vs last qtr

NEW

Held since

Q2 '26

ADAR1 Capital Management, LLC

167.9K

% of company

3.80%

Change vs last qtr

Unchanged

Held since

2024

25 more super investors behind a free account

See every manager holding Kiora Pharmaceuticals, Inc., how their position has changed, and how long they've held it.

Institutional Funds

Mutual funds and ETFs reporting KPRX on Form N-PORT; together they hold 1.3% of the company

Fund	Position value	Shares	% of company	% of the fund	As of
VE Vanguard Extended Market Index Fund Vanguard Index Funds	$52.2K	19.9K	0.45%	0.00%	June 30, 2026
FE Fidelity Extended Market Index Fund Fidelity Concord Street Trust	$52.2K	20.8K	0.47%	0.00%	August 31, 2026

Vanguard Extended Market Index Fund

Vanguard Index Funds

Position value

$52.2K

% of company

0.45%

% of the fund

0.00%

As of

June 30, 2026

Fidelity Extended Market Index Fund

Fidelity Concord Street Trust

Position value

$52.2K

% of company

0.47%

% of the fund

0.00%

As of

August 31, 2026

8 more funds behind a free account

See every fund holding Kiora Pharmaceuticals, Inc. and how much of the fund the position is.

Insiders and 5%+ holders

From Forms 3/4/5 and Schedules 13D/G

Holder	Shares	% of company	Change vs last qtr	8 quarters	Held since	% of their book
SB Strem Brian M. Insider	58.8K	1.33%	—	—	—	—
Insider holdings come from Form 3/4/5 filings, which are not quarterly. Share of the company1.330% Strem Brian M.'s insider activity →
DE Daniels Eric Joseph Insider	31.7K	0.72%	—	—	—	—
Insider holdings come from Form 3/4/5 filings, which are not quarterly. Share of the company0.720% Daniels Eric Joseph's insider activity →

Strem Brian M.

Insider

58.8K

% of company

1.33%

Change vs last qtr

—

Held since

—

Daniels Eric Joseph

Insider

31.7K

% of company

0.72%

Change vs last qtr

—

Held since

—

1 more holders behind a free account

See every insider and 5%+ holder of Kiora Pharmaceuticals, Inc..

Comments